MOUNJARO

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Jul 28, 2023

   2 yr 11 mo ago

2. Today

3. Exclusivity ends · NCE

   New chemical entity exclusivity (5 years)

   May 13, 2027

   in 11 mo

4. Exclusivity ends · NPP

   New patient population exclusivity (3 years)

   Dec 19, 2028

   in 2 yr 6 mo

5. Patent 9474780 expires

   Listed drug substance patent expiration.

   Jan 05, 2036

   in 9 yr 8 mo

6. Patent 11357820 expires

   Listed drug substance patent expiration.

   Jun 14, 2039

   in 13 yr 2 mo

7. Patent 12453755 expires

   Listed method-of-use patent (U-4386) expiration.

   Jun 14, 2039

   in 13 yr 2 mo

8. Patent 12453755 expires

   Listed method-of-use patent (U-4380) expiration.

   Jun 14, 2039

   in 13 yr 2 mo

9. Patent 12453755 expires

   Listed method-of-use patent (U-4383) expiration.

   Jun 14, 2039

   in 13 yr 2 mo

10. Patent 12453755 expires

    Listed method-of-use patent (U-4378) expiration.

    Jun 14, 2039

    in 13 yr 2 mo

11. Patent 12453755 expires

    Listed method-of-use patent (U-4375) expiration.

    Jun 14, 2039

    in 13 yr 2 mo

12. Patent 12453755 expires

    Listed method-of-use patent (U-4385) expiration.

    Jun 14, 2039

    in 13 yr 2 mo

13. Patent 12453755 expires

    Listed method-of-use patent (U-4384) expiration.

    Jun 14, 2039

    in 13 yr 2 mo

14. Patent 12453755 expires

    Listed method-of-use patent (U-4376) expiration.

    Jun 14, 2039

    in 13 yr 2 mo

15. Patent 12453755 expires

    Listed method-of-use patent (U-4382) expiration.

    Jun 14, 2039

    in 13 yr 2 mo

16. Patent 12453755 expires

    Listed method-of-use patent (U-4379) expiration.

    Jun 14, 2039

    in 13 yr 2 mo

17. Patent 12453755 expires

    Listed method-of-use patent (U-4381) expiration.

    Jun 14, 2039

    in 13 yr 2 mo

18. Patent 12453755 expires

    Listed method-of-use patent (U-4377) expiration.

    Jun 14, 2039

    in 13 yr 2 mo

19. Patent 12453756 expires

    Listed drug product patent expiration.

    Jun 14, 2039

    in 13 yr 2 mo

20. Patent 12629404 expires

    Listed drug product patent expiration.

    Jun 14, 2039

    in 13 yr 2 mo

21. Patent 12629404 expires

    Listed drug product patent expiration.

    Jun 14, 2039

    in 13 yr 2 mo

22. Patent 12343382 expires

    Listed method-of-use patent (U-4229) expiration.

    Jul 22, 2039

    in 13 yr 3 mo

23. Patent 12343382 expires

    Listed method-of-use patent (U-4230) expiration.

    Jul 22, 2039

    in 13 yr 3 mo

24. Patent 12343382 expires

    Listed method-of-use patent (U-4231) expiration.

    Jul 22, 2039

    in 13 yr 3 mo

25. Patent 12343382 expires

    Listed method-of-use patent (U-4232) expiration.

    Jul 22, 2039

    in 13 yr 3 mo

26. Patent 12343382 expires

    Listed method-of-use patent (U-4401) expiration.

    Jul 22, 2039

    in 13 yr 3 mo

27. Patent 12343382 expires

    Listed method-of-use patent (U-4400) expiration.

    Jul 22, 2039

    in 13 yr 3 mo

28. Patent 12616740 expires

    Listed method-of-use patent (U-4500) expiration.

    Jul 22, 2039

    in 13 yr 3 mo

29. Patent 12616740 expires

    Listed method-of-use patent (U-4501) expiration.

    Jul 22, 2039

    in 13 yr 3 mo

30. Patent 12616740 expires

    Listed method-of-use patent (U-4502) expiration.

    Jul 22, 2039

    in 13 yr 3 mo

31. Patent 12295987 expires

    Listed method-of-use patent (U-4193) expiration.

    Dec 30, 2041

    in 15 yr 9 mo

32. Patent 12295987 expires

    Listed method-of-use patent (U-4192) expiration.

    Dec 30, 2041

    in 15 yr 9 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

• ZEPBOUNDBrand (NDA)

  NDA 217806 · ELI LILLY AND CO

  2024

Marketing exclusivity (2)

• NCENew chemical entity exclusivity (5 years)

  May 13, 2027

  in 11 mo

• NPPNew patient population exclusivity (3 years)

  Dec 19, 2028

  in 2 yr 6 mo

Listed patents (28)